Berry Lance A 4

What Happened
Lance A. Berry, a director of Treace Medical Concepts, Inc. (TMCI), received an award of 30,000 restricted stock units (RSUs) on May 19, 2026. The award is reported as an acquisition (code A) at $0.00 per share (total reported consideration $0). The RSUs convert 1:1 into common shares upon settlement, subject to vesting and the director's continued service.

Key Details

• Transaction date: 2026-05-19; transaction type: Award/Grant (A); reported price: $0.00; quantity: 30,000 RSUs.
• Vesting: RSUs vest 100% on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting, subject to continued service. (Footnote F1)
• Deferral: Reporting person voluntarily elected to defer receipt of the shares issuable upon settlement of the RSUs until the earlier of a change in control or the reporting person's separation of service. (Footnote F1)
• Footnote F2 confirms the 30,000 units are RSUs.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Filing timeliness: Reported with form date 2026-05-19 (same date as the grant), indicating a timely report.

Context
RSUs are a form of equity compensation that become actual shares only upon vesting/settlement; this award does not involve an immediate cash purchase or sale. Because the director elected to defer delivery of the underlying shares, even after vesting the shares may not be issued until a change in control or the director's separation from service. This is an equity grant, not a market purchase or sale, and does not by itself indicate the director's market sentiment.